In particular, people with multiple sclerosis on natalizumab had lower CD6, CDCP1, CXCL13, CXCL9, NfL, TNFRSF10a, TNFSF13B and VCAN (P < 0.036). This evidence concerns the gene CXCL9 and multiple sclerosis.